Details
Stereochemistry | RACEMIC |
Molecular Formula | C14H12ClNO2 |
Molecular Weight | 261.704 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(O)C2=C(C=N1)C(OC2)C3=CC=C(Cl)C=C3
InChI
InChIKey=CVKNDPRBJVBDSS-UHFFFAOYSA-N
InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3
Molecular Formula | C14H12ClNO2 |
Molecular Weight | 261.704 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Cicletanine is a diuretic, developed by Ipsen for the treatment of hypertension. The drug was marketed in France by Recordati under the name Tenstaten. The mechanism(s) by which cicletanine exerts its biological effects has not been definitely established. The salidiuretic activity appears to be the result of an action of the sulfoconjugated metabolite of cicletanine, which inhibits the apical Na+-dependent Cl-/HCO3- anion exchanger in the distal convoluted tubule. The mechanism of the vasodilating effect of cicletanine may include stimulation of vascular prostaglandin synthesis, inhibition of the low Km cyclic GMP phosphodiesterases, and blockade of Ca2+ channels either directly or indirectly. The drug has also been shown to interact with other proteins, including alpha-adrenergic, vascular histamine, and muscarinic receptors.
CNS Activity
Originator
Sources: https://www.ipsen.com/websites/IPSENCOM-PROD/wp-content/uploads/2016/06/29140317/Ipsen_AR_2005_EN.pdf
Curator's Comment: In october 2005 Ipsen and Recordati announced the signature of an agreement by which Ipsen grants to Recordati the exclusive marketing and selling rights in France of Tenstaten (cicletanine).
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
[Comparison of the effects of cicletanine and captopril on kidney and heart lesions in spontaneously hypertensive rats (SHR-SP)]. | 1989 Nov |
|
Renal-protective effect of nondepressor dose of cicletanine in diabetic rats with hypertension. | 2000 Mar |
|
Effect of cicletanine on the nitric oxide pathway in human umbilical vein endothelial cells. | 2001 Aug |
|
Nitric oxide, peroxynitrite and cGMP in atherosclerosis-induced hypertension in rabbits: beneficial effects of cicletanine. | 2001 Jan-Feb |
|
Cicletanine stimulates nitric oxide release and scavenges superoxide in endothelial cells. | 2001 Jun |
|
Diuretics in the therapy of hypertension. | 2002 Mar |
|
Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension. | 2003 Mar |
|
Protective effect of cicletanine on renal function in diabetic spontaneously hypertensive rats. | 2004 Nov |
|
Insulin sensitization induced by oral cicletanine in conscious rabbits. | 2006 Sep |
|
Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. | 2007 |
|
Cicletanine for the treatment of pulmonary arterial hypertension. | 2008 Oct 27 |
|
Update on pulmonary hypertension complicating chronic obstructive pulmonary disease. | 2009 |
|
Blood pressure lowering efficacy of loop diuretics for primary hypertension. | 2009 Oct 7 |
|
Emerging therapies for the treatment of pulmonary hypertension. | 2010 Mar |
Patents
Sample Use Guides
The treatment is initiated with 50 mg/day, but the effective dosage is usually 100 mg/day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8391656
The effect of cicletanine on active tension was investigated in rat thoracic aortas. At concentrations from 3*10(-5) M to 3*10(-4) M the drug caused a concentration-related relaxation of noradrenaline, serotonin and prostaglandin F2alpha-induced contractions.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:12:19 GMT 2023
by
admin
on
Fri Dec 15 16:12:19 GMT 2023
|
Record UNII |
CHG7QC509W
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC03BX03
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
||
|
NCI_THESAURUS |
C448
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
||
|
WHO-ATC |
C03BX03
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C77557
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | |||
|
100000081885
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | |||
|
634
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | |||
|
BB-93
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | |||
|
21914
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB06237MIG
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | |||
|
CHG7QC509W
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | |||
|
DTXSID70868972
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | |||
|
C038068
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | |||
|
54910
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | |||
|
89943-82-8
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | |||
|
m3537
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
5596
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | |||
|
CICLETANINE
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | |||
|
DB12766
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL191886
Created by
admin on Fri Dec 15 16:12:19 GMT 2023 , Edited by admin on Fri Dec 15 16:12:19 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |